



COPY OF PAPERS  
ORIGINALLY FILED

1656 #3

Attorney Docket No. GENO200.2/CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: MESSIER ET AL.

SERIAL NO.: 10/098,600

FILED: MARCH 14, 2002

TITLE: METHODS TO IDENTIFY POLYNUCLEOTIDE  
AND POLYPEPTIDE SEQUENCES WHICH MAY  
BE ASSOCIATED WITH PHYSIOLOGICAL AND  
MEDICAL CONDITIONS

EXAMINER:

ART UNIT: 1656

CONF NO.: 9206

RECEIVED

JUL 19 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an

37 CFR 1.8

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on: 7/10/02

Signature: *Tasha L. Cove*

Name: Tasha L. Cove

admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

  
Margaret M. Wall, #33,462  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: 303-268-0066  
Facsimile: 303-268-0065

cc: Ginny Orndorff

S:\CLIENT FOLDERS\EVOLUTIONARY GENOMICS\200-2\CIP2\SUPP IDS.DOC

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b> List of Information Cited by Applicant Page 1 of 2	<b>ATTY. DOCKET NO.</b> GENO200.2/CIP2	<b>SERIAL NO.</b> 10/098,600
	<b>APPLICANT</b> MESSIER ET AL.	
	<b>FILING DATE</b> MARCH 14, 2002	<b>GROUP</b> 1656

**RECEIVED**

JUL 19 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
AA						
AB						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AC						
	AD						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AE	✓	Dennis (1999) Nat. Gen. 22:10
AF	✓	Favre et al. (2001) CR Acad. Sci. 324:1141-1148
AG	✓	Galun et al. (1995) J. Infectious Diseases 172:25-30
AH	✓	Hacia et al. (Feb. 1998) Nat. Gen. 18:155-158
AI	✓	Labonte et al. (2002) J. Med. Virol. 66:312-319
AJ	✓	Lanford et al. (1991) J. Med. Virology 34:148-153
AK	✓	Mercer et al. (Aug. 2001) Nat. Med. 7(8):927-933
AL	✓	Shen et al. (1998) Oncogene 17:3115-3124
AM	✓	Shimizu et al. (April 1985) Med. Sci. 82:2138-2142
AN	✓	Takahashi et al. (1990) J. General Virology 71:2005-2011
AO	✓	Thompson et al. (April 1995) Nat. Gen. 9:444-450
AP	✓	Walker (1997) Springer Semin Immunopathology 19(1):85-98
AQ	✓	Xu et al. (March 1999) Mol. Cell 3:389-395
AR	✓	Xu et al. (May 1999) Nat. Gen. 22:37-43
AS		
AT		
AU		
AV		
AW		
AX		
AY		
AZ		
AAA		
AAA		
AAB		

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.